FibroBiologics, Common Revenue vs. Cash Flow From Operations
| FBLG Stock | 2.84 0.19 7.17% |
Total Revenue | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
For FibroBiologics, Common profitability analysis, we use financial ratios and fundamental drivers that measure the ability of FibroBiologics, Common to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well FibroBiologics, Common Stock utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between FibroBiologics, Common's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of FibroBiologics, Common Stock over time as well as its relative position and ranking within its peers.
FibroBiologics, |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroBiologics, Common. If investors know FibroBiologics, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroBiologics, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.59) | Return On Assets (0.62) | Return On Equity (4.34) |
The market value of FibroBiologics, Common is measured differently than its book value, which is the value of FibroBiologics, that is recorded on the company's balance sheet. Investors also form their own opinion of FibroBiologics, Common's value that differs from its market value or its book value, called intrinsic value, which is FibroBiologics, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroBiologics, Common's market value can be influenced by many factors that don't directly affect FibroBiologics, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroBiologics, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroBiologics, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroBiologics, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
FibroBiologics, Common Cash Flow From Operations vs. Revenue Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining FibroBiologics, Common's current stock value. Our valuation model uses many indicators to compare FibroBiologics, Common value to that of its competitors to determine the firm's financial worth. FibroBiologics, Common Stock is currently under evaluation in revenue category among its peers. It is one of the top stocks in cash flow from operations category among its peers . At this time, FibroBiologics, Common's Total Revenue is most likely to stay steady in the upcoming years. Comparative valuation analysis is a catch-all technique that is used if you cannot value FibroBiologics, Common by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.FibroBiologics, Revenue vs. Competition
FibroBiologics, Common Stock is currently under evaluation in revenue category among its peers. Market size based on revenue of Health Care industry is currently estimated at about 36.35 Billion. FibroBiologics, Common adds roughly 0.0 in revenue claiming only tiny portion of equities under Health Care industry.
FibroBiologics, Cash Flow From Operations vs. Revenue
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
FibroBiologics, Common |
| = | null |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
FibroBiologics, Common |
| = | (6.4 M) |
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
FibroBiologics, Cash Flow From Operations Comparison
FibroBiologics, Common is currently under evaluation in cash flow from operations category among its peers.
FibroBiologics, Common Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in FibroBiologics, Common, profitability is also one of the essential criteria for including it into their portfolios because, without profit, FibroBiologics, Common will eventually generate negative long term returns. The profitability progress is the general direction of FibroBiologics, Common's change in net profit over the period of time. It can combine multiple indicators of FibroBiologics, Common, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 1.3 M | 1.2 M | |
| Net Interest Income | -147 K | -154.3 K | |
| Operating Income | -8.9 M | -8.4 M | |
| Net Loss | -16.5 M | -15.7 M | |
| Income Before Tax | -16.5 M | -15.7 M | |
| Total Other Income Expense Net | -7.6 M | -7.2 M | |
| Net Loss | -16.5 M | -15.7 M | |
| Net Loss | (0.58) | (0.55) | |
| Income Quality | 0.39 | 0.76 |
FibroBiologics, Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on FibroBiologics, Common. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of FibroBiologics, Common position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the FibroBiologics, Common's important profitability drivers and their relationship over time.
Use FibroBiologics, Common in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if FibroBiologics, Common position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in FibroBiologics, Common will appreciate offsetting losses from the drop in the long position's value.FibroBiologics, Common Pair Trading
FibroBiologics, Common Stock Pair Trading Analysis
The ability to find closely correlated positions to FibroBiologics, Common could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace FibroBiologics, Common when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back FibroBiologics, Common - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling FibroBiologics, Common Stock to buy it.
The correlation of FibroBiologics, Common is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as FibroBiologics, Common moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if FibroBiologics, Common moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for FibroBiologics, Common can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your FibroBiologics, Common position
In addition to having FibroBiologics, Common in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Commodities Funds Thematic Idea Now
Commodities Funds
Funds or Etfs investing in commodities such as oil, gold, corn, soy, and agricultural goods. The Commodities Funds theme has 48 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Commodities Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in FibroBiologics, Stock
When determining whether FibroBiologics, Common is a strong investment it is important to analyze FibroBiologics, Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact FibroBiologics, Common's future performance. For an informed investment choice regarding FibroBiologics, Stock, refer to the following important reports:Check out Investing Opportunities. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
To fully project FibroBiologics, Common's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of FibroBiologics, Common at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include FibroBiologics, Common's income statement, its balance sheet, and the statement of cash flows.